148
Participants
Start Date
September 22, 2023
Primary Completion Date
April 14, 2025
Study Completion Date
May 16, 2025
Insulin Icodec
Participants will receive subcutaneously insulin icodec once weekly for 52 weeks.
Semaglutide
Participants will receive once weekly semaglutide subcutaneously starting from 0.25 mg and dose increased up to 1 mg for 26 weeks.
King Chulalongkorn Memorial Hospital, Bangkok
Rajavithi Hospital, Bangkok
Ramathibodi Hospital, Bangkok
CHC Zvezdara, Clinical department for endocrinology, Belgrade
Clinical Hospital Centre Zemun, Belgrade
Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis., Novi Sad
Clinical Centre Kragujevac, Internal Diseases Clinic, Endocrinology department, Kragujevac
Universiti Teknologi MARA, Sungai Buloh Campus, Sungai Buloh
Hospital Universiti Kebangsaan Malaysia, Cheras
Hospital Putrajaya, Putrajaya
Hospital Miri, Miri
Edumed Broumov, Broumov
DIALINE s.r.o., Plzeň 3
Diabet2 s.r.o., Prague
Diabetologická a endokrinologická ambulance Praha, Prague
EUC Klinika Praha a.s., Prague
Comfort Care Praha s.r.o., Praha 4 - Chodov
Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET, Krakow
"Osrodek Badan Klinicznych METABOLICA lek. Robert Witek", Tarnów
Specjalistyczny Gabinet Diabetologiczny Radoslaw Rumianowski, Gorzów Wielkopolski
Specjalistyczny Gabinet Diabetologiczny Radoslaw Rumianowski, Gorzów Wielkopolski
NBR Polska, Warsaw
NBR Polska Tomasz Klodawski, Warsaw
Osteo-Medic s.c. A. Racewicz, J. Supronik, Bialystok
NZOZ Gdanska Poradnia Cukrzycowa Sp.z o.o., Gdansk
NZOZ Gdanska Poradnia Cukrzycowa, Gdansk
Centrum Medyczne Pratia Katowice, Katowice
Santa Sp. z o.o, Santa Familia Centrum Badan, Profilaktyki i Leczenia, Lodz
Santa Sp. z o.o, Santa Familia Centrum Badan, Profilaktyki i Leczenia, Lodz
Lead Sponsor
Novo Nordisk A/S
INDUSTRY